Form 8-K

8-K — TELA Bio, Inc.

Accession: 0001104659-26-090056

Filed: 2026-08-04

Period: 2026-08-03

CIK: 0001561921

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Documents

8-K — tm2622121d1_8k.htm (Primary)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2622121d1_8k.htm · Sequence: 1

false

0001561921

2026-08-03

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 3, 2026

TELA

Bio, Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-39130

45-5320061

(State or other jurisdiction of

incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

Great Valley Parkway, Suite 24

Malvern,

Pennsylvania

19355

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (484) 320-2930

Not Applicable

(Former name or former address, if changed

since last report.)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act

(17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange

Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange

Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of

the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which

registered

Common

Stock, par value $0.001 per share

TELA

Nasdaq

Global Market

Indicate by check mark whether the registrant is

an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02

Departure of Directors or

Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Chief Executive Officer and Director

On August 3, 2026, the Board of Directors (the “Board”)

of TELA Bio, Inc. (the “Company”) determined that, Antony Koblish will no longer serve as the Company’s

Chief Executive Officer and the principal executive officer, effective on August 3, 2026 (the “Effective Date”).

In addition, on August 3, 2026, Mr. Koblish, a member of the Board, tendered his resignation from the Board, effective as of 12:01 am

ET on the Effective Date. Mr. Koblish’s decision to resign from the Board did not result from any disagreement with the Company

on any matters relating to the Company’s operations, policies or practices.

In connection with Mr. Koblish’s termination as the Company’s

Chief Executive Officer, the Company expects to enter into a separation agreement with Mr. Koblish, but the terms have not been finalized

as of the date of this Current Report on Form 8-K. The material terms of such separation agreement will be disclosed in an amendment

to this Current Report on Form 8-K. The termination of Mr. Koblish is being treated as a termination without cause, and Mr. Koblish’s

existing equity awards shall remain outstanding prior to the entry into the separation agreement, which is expected to address the treatment

of his existing equity awards in connection with his termination.

The Board and Company’s decision that Mr. Koblish will no longer

serve as the Company’s Chief Executive Officer is not the result of any disagreement with Mr. Koblish on any matter relating to

the Company’s operations, policies, or practices.

Appointment of Chief Executive Officer and Director

On August 3, 2026, the Board of the Company approved the

appointment of Heather Getz the Company’s Chief Executive Officer and principal executive officer, effective on the Effective

Date. In addition, on August 3, 2026, in connection with Mr. Koblish’s resignation from the Board, the Board appointed Ms. Getz as a Class

II director, with a term expiring at the 2027 Annual Meeting of the Company, effective immediately following the effectiveness of

Mr. Koblish’s resignation from the Board on the Effective Date.

Ms. Getz has over 25 years of experience in publicly traded healthcare

and medical device companies where she created long-term value through her financial and operational leadership. During her career, Mr.

Getz has been integral in strategy development and successfully led the acquisition and/or integration of over 40 companies and secured

over $1 billion in financing. Ms. Getz has also led several business restructurings removing hundreds of millions of costs from businesses

while growing revenue. She was instrumental in turning around and growing BioTelemetry, Inc. from a market capitalization of $50 million

to $2.8 billion upon its sale to Koninklijke Philips N.V. (NYSE: PHG) in 2021. Ms. Getz has served on the board of directors of Myomo,

Inc. (NYSE: MYO), since March 2024, where she is chair of the Audit Committee and a member of the Nominating and Governance Committee.

She also serves as a director and Chairman of the Audit Committee and member of the Compensation committee at Vital Connect, Inc. In

August 2025, Ms. Getz retired as the Chief Financial and Operations Officer and Corporate Secretary of Butterfly Network, Inc. (NYSE:

BFLY) where she served since May 2022. Previously, Ms. Getz was Chief Financial Officer and President of North America at Healthy.io

Ltd., a privately-held medical technology company, from November 2021 to April 2022. Before joining Healthy.io Ltd., from May 2009 to

November 2021, Ms. Getz held executive leadership positions at BioTelemetry, Inc., a publicly-traded medical technology company, including

serving as Chief Financial and Administrative Officer from January 2019 to July 2021, Chief Financial Officer from January 2010 to January

2019, and Vice President Finance from May 2009 to January 2010. Prior to BioTelemetry, Ms. Getz has also held various leadership positions

at Alita Pharmaceuticals, VIASYS Healthcare Inc., and Sunoco, Inc. Ms. Getz received her undergraduate degree in Accountancy and a Master

of Business Administration (MBA) degree from Villanova University. She is a certified public accountant (CPA) and holds a Director Certification

from the National Association of Corporate Directors (NACD. CD).

There are no arrangements or understandings between Ms. Getz and any

other persons pursuant to which Ms. Getz was appointed as Chief Executive Officer of the Company. In addition, there are no family relationships

between Ms. Getz and any director or executive officer of the Company, and there are no transactions involving Ms. Getz requiring disclosure

under Item 404(a) of Regulation S-K.

In addition, on August 3, 2026, the Company entered into an employment

agreement with Ms. Getz (the “ Getz Employment Agreement”), providing for, among other things, an annual base

salary of $650,000 and a target cash bonus opportunity of 100% of Ms. Getz current annual salary, pro-rated for any partial calendar

year of service. The annual bonus for the bonus year ending December 31, 2026 will be prorated based on a fraction, the numerator of

which is five months and the denominator of which is 12 months. Pursuant to the Getz Employment Agreement, if Ms. Getz is terminated

without “Cause” or resigns for “Good Reason” (as such terms are defined in the Getz Employment Agreement), she

will be entitled to (i) all accrued and unpaid base salary through the termination date; (ii) any accrued and unpaid bonus for the preceding

year; (iii) a pro-rated portion of the annual bonus for the bonus year in which the termination date occurs (based on the number of calendar

days worked in such year divided by 365), equal to the then-current target bonus; (iv) 12 months of severance based on her then-current

base salary; and (v) continuation of health insurance until the earliest of (A) the end of 12 months; (B) Ms. Getz’s eligibility

for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of Ms. Getz’s continuation

rights under COBRA. In the event that Ms. Getz is terminated without “Cause” or resigns for “Good Reason” during

a “Change of Control Period” (as such terms are defined in the Getz Employment Agreement), then she is entitled to (i) 18

months of severance based on her then-current base salary (in lieu of the 12-month severance); (ii) an amount equal to 150% of Ms. Getz’s

then-current target bonus, payable in accordance with the Company’s annual bonus payment practices; (iii) a pro-rated portion of

the annual bonus that she would have earned for the year of termination had she remained employed, as determined by the Board in good

faith; (iv) the acceleration of vesting and exercisability of 100% of her then-outstanding equity awards, provided, however, that for

any awards that vest in whole or in part based on the attainment of performance-vesting conditions, only the service-vesting conditions

(if any) of such award shall be deemed satisfied, while the performance-vesting conditions of such award shall remain eligible to be

achieved based upon actual performance over the remainder of the applicable performance period; and (v) continuation of health insurance

until the earliest of (A) the end of 12 months; (B) Ms. Getz’s eligibility for group medical plan benefits under any other employer’s

group medical plan; or (C) the cessation of Ms. Getz’s continuation rights under COBRA.

In addition, on August 3, 2026 (the “Grant Date”),

in connection with Ms. Getz’s appointment and pursuant to the employment agreement described below, Ms. Getz was granted initial

equity awards, each as an inducement grant pursuant to the “inducement exception” provided under Rule 5635(c)(4) of The Nasdaq

Stock Market LLC, consisting of (i) options to purchase 1,365,000 shares of Company’s common stock, par value $0.001 per share

(the “Common Stock”), with a per share exercise price equal to the closing price of the Company’s Common Stock

on the Grant Date and vesting 25% on the first anniversary of the Grant Date, with the remaining 75% vesting in 36 equal monthly installments

thereafter (the “Standard Options”), (ii) premium-priced options to purchase 1,005,000 shares of Common Stock,

with a per share exercise price equal to the greater of (a) $0.90 and (b) a 15% premium to the fair market value of the Company’s

Common Stock on the Grant Date, vesting 25% on the first anniversary of the Grant Date, with the remaining 75% vesting in 36 equal monthly

installments thereafter (the “Premium Options” and, together with the Standard Options, the “Option

Grants”) and (iii) restricted stock unit awards with respect to 500,000 shares of Common Stock (the “RSU Grant”,

together with the Options Grants, “the Initial Grants”), which vests in four equal annual installments, beginning

on the first anniversary of the Grant Date, over the four years following the Grant Date. The vesting of each of the Option Grants and

RSU Grant are subject to Ms. Getz’s continued service with the Company through the applicable vesting dates, and the Option Grants

each expire on August 3, 2036. In addition, in the event the Company consummates

one or more public or private equity financings within the 18-month period following August 3, 2026, Ms. Getz shall be entitled to additional

equity grants (the “Top-Up Grants”) such that the aggregate number of shares subject to the Initial Grants

and Top-Up Grants is equal to 5% of the total number of shares issued and outstanding of the Company as of immediately following such

equity financing (including, for this purpose, shares underlying pre-funded warrants). Such Top-Up Grants shall be in the form of options,

premium options and RSUs, to be granted in the same proportion as the Initial Grants.

The foregoing description of the Getz Employment Agreement does not

purport to be complete and is qualified in its entirety by reference to the full text of the Getz Employment Agreement, which will be

filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TELA BIO, INC.

By:

/s/ Roberto Cuca

Name:

Roberto Cuca

Title:

Chief Operating Officer; Chief Financial Officer and Corporate Secretary

Date: August 4, 2026

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Cover

Aug. 03, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 03, 2026

Entity File Number

001-39130

Entity Registrant Name

TELA

Bio, Inc.

Entity Central Index Key

0001561921

Entity Tax Identification Number

45-5320061

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Great Valley Parkway

Entity Address, Address Line Two

Suite 24

Entity Address, City or Town

Malvern

Entity Address, State or Province

Entity Address, Postal Zip Code

19355

City Area Code

484

Local Phone Number

320-2930

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

TELA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration